Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RESMED, INC.

(RMD)
  Report
Real-time Estimate Cboe BZX  -  11:40 2022-11-30 am EST
224.57 USD   +0.61%
11/23Insider Sell: Resmed
MT
11/22ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions
GL
11/22ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

ResMed Announces Participation in the 20th Annual Morgan Stanley Global Healthcare Conference

09/06/2022 | 09:01am EST

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on Monday, September 12, 2022, beginning at approximately 8:45 a.m. (Eastern Daylight Time) at the Sheraton New York in New York City.

More information about this event, including a live webcast, may be accessed by visiting http://investor.resmed.com. The webcast replay will be available approximately 3 hours after the live webcast ends and will be accessible through March 11, 2023.

About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

For InvestorsFor Media
Amy WakehamJayme Rubenstein
+1 858.836.5000+1 858.836.6798
investorrelations@resmed.com news@resmed.com  


All news about RESMED, INC.
11/23Insider Sell: Resmed
MT
11/22ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Ma..
GL
11/22ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Ma..
AQ
11/17Resmed : Submission of Matters to a Vote of Security Holders - Form 8-K
PU
11/17Resmed Inc : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
11/17ResMed Inc Provides Information to the Shareholders
CI
11/17Insider Sell: Resmed
MT
11/16ResMed Opens Manufacturing Centre in Singapore, Expanding Manufacturing Footprint to Su..
CI
11/16Resmed Inc. Appoints Sandeep Gulati as General Manager, South Asia
CI
11/16Resmed : Opens Manufacturing Centre in Singapore, Expanding Manufacturing Footprint to Sup..
PU
More news
Analyst Recommendations on RESMED, INC.
More recommendations
Financials (USD)
Sales 2023 3 987 M - -
Net income 2023 892 M - -
Net Debt 2023 808 M - -
P/E ratio 2023 36,1x
Yield 2023 0,81%
Capitalization 32 695 M 32 695 M -
EV / Sales 2023 8,40x
EV / Sales 2024 7,57x
Nbr of Employees 8 160
Free-Float 76,8%
Chart RESMED, INC.
Duration : Period :
ResMed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESMED, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 223,20 $
Average target price 251,67 $
Spread / Average Target 12,8%
EPS Revisions
Managers and Directors
Michael J. Farrell Director-Business Development
Robert Andrew Douglas Vice President-Corporate Marketing
Brett A. Sandercock Chief Financial Officer
Peter C. Farrell Non-Executive Chairman
Carlos M. Nunez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
RESMED, INC.-13.41%32 695
THERMO FISHER SCIENTIFIC-19.11%212 687
DANAHER CORPORATION-21.27%188 557
INTUITIVE SURGICAL, INC.-26.90%91 456
BOSTON SCIENTIFIC CORPORATION3.08%63 738
SIEMENS HEALTHINEERS AG-23.37%58 323